Search Results

Beltsville, MD — Maryland Oncology Hematology (MOH) has opened a new state‑of‑the‑art Next Generation Sequencing (NGS) laboratory, marking a significant step forward in making advanced genomic testing faster and more accessible for cancer patients throughout the region. With this addition, MOH becomes one of the few private oncology practices in the United States to operate its…

Head and neck cancers are actually multiple kinds of cancers that develop in the throat, nose, mouth, sinuses, or larynx. These cancers have traditionally been linked to tobacco use, alcohol consumption, and the human papillomavirus (HPV). However, there may also be a link between poor oral hygiene and your risk of developing one of these…

A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR) (NVL-655-04) MOA: NVL-655 is an ALK TKI, designed for broader coverage of ALK resistance mutations, activity in the CNS, and selectivity over TRKB. Key Eligibility Criteria:…

A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02) OP-1250-302 MOA: Palazestrant (OP-1250) is an oral complete estrogen receptor antagonist (CERAN) and a selective estrogen receptor degrader (SERD) Key Eligibility Criteria: Confirmed ER+ (≥1%) /HER2-negative MBC and one…

INCA033890-303: A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer MOA: INCA33890 is a Fc-silenced, IgG1 bispecific antibody that can simultaneously bind to both PD-1 and TGFβR2. Key Eligibility Criteria: Histologically or cytologically confirmed metastatic colorectal adenocarcinoma not amenable…

A Phase 2/3 Interventional Study Of PF-08634404 In Combination With Chemotherapy In Treatment-Naïve Participants With Locally Advanced Or Metastatic Gastric, Gastroesophageal Junction, Or Esophageal Adenocarcinoma MOA: PF-08634404 is a recombinant anti-PD-1 and anti-VEGF human mAb Key Eligibility Criteria: Histologically or cytologically confirmed gastric, GEJ, or esophageal adenocarcinoma that is locally advanced unresectable or metastatic No…